Adaptive Biotechnologies Corporation

    Jurisdiction
    United States
    LEI
    549300ZTF7OT1FW66Q96
    ISIN
    US00650F1093 (ADPT)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    InsiderPie Expert Score
    trending_flat 55 / 100
    Better than peer group:
    50 / 100
    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    6 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    5 / 7

    Profile

    Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. Read full profile

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Fundamentals

    Net revenue
    €176.08M
    Gross margin
    66.0%
    EBIT
    -€103.91M
    EBIT margin
    -59.0%
    Net income
    -€104.01M
    Net margin
    -59.1%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €231.71M +31.6% -€81.71M -21.4%
    €282.43M +21.9% -€50.11M -38.7%
    €333.68M +18.1% -€14.95M -70.2%

    Dividends

    No dividend payouts

    Earnings Calls

    Latest earnings call: May 7, 2024

    Investor transactions

    Name Shares Value Last change Change type
    Cathie Wood 7.7M $57.45M -1.7M Sell
    Peter Brown 106K $786.73K -124K Sell

    Add to watchlist

    Notifications